Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 3
2003 5
2004 5
2005 15
2006 9
2007 5
2008 6
2009 10
2010 11
2011 18
2012 13
2013 9
2014 13
2015 10
2016 14
2017 15
2018 8
2019 7
2020 12
2021 16
2022 11
2023 5
2024 6

Text availability

Article attribute

Article type

Publication date

Search Results

190 results

Results by year

Filters applied: . Clear all
Page 1
AMPK inhibition sensitizes acute leukemia cells to BH3 mimetic-induced cell death.
Jia J, Ji W, Saliba AN, Csizmar CM, Ye K, Hu L, Peterson KL, Schneider PA, Meng XW, Venkatachalam A, Patnaik MM, Webster JA, Smith BD, Ghiaur G, Wu X, Zhong J, Pandey A, Flatten KS, Deng Q, Wang H, Kaufmann SH, Dai H. Jia J, et al. Among authors: smith bd. Cell Death Differ. 2024 Apr;31(4):405-416. doi: 10.1038/s41418-024-01283-9. Epub 2024 Mar 27. Cell Death Differ. 2024. PMID: 38538744
Efficacy and safety of bosutinib in patients treated with prior imatinib and/or dasatinib and/or nilotinib: Subgroup analyses from the phase 4 BYOND study.
Smith BD, Brümmendorf TH, Roboz GJ, Gambacorti-Passerini C, Charbonnier A, Viqueira A, Leip E, Purcell S, Goldman EH, Giles F, Ernst T, Hochhaus A, Rosti G. Smith BD, et al. Leuk Res. 2024 Apr;139:107481. doi: 10.1016/j.leukres.2024.107481. Epub 2024 Mar 11. Leuk Res. 2024. PMID: 38484432 Clinical Trial.
Chronic Myeloid Leukemia, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology.
Shah NP, Bhatia R, Altman JK, Amaya M, Begna KH, Berman E, Chan O, Clements J, Collins RH, Curtin PT, DeAngelo DJ, Drazer M, Maness L, Metheny L, Mohan S, Moore JO, Oehler V, Pratz K, Pusic I, Rose MG, Shomali W, Smith BD, Styler M, Talpaz M, Tanaka TN, Tantravahi S, Thompson J, Tsai S, Vaughn J, Welborn J, Yang DT, Sundar H, Gregory K. Shah NP, et al. Among authors: smith bd. J Natl Compr Canc Netw. 2024 Feb;22(1):43-69. doi: 10.6004/jnccn.2024.0007. J Natl Compr Canc Netw. 2024. PMID: 38394770
Project Confirm: Accelerated Drug Approvals for CML-Response.
Sweet KL, Cortes JE, Apperley JF, Mann M, Mauro MJ, Oehler VG, Ruiz C, Schiffer CA, Ehrlich LA, Pamuk GE, Wynne J, Mehta GU, Okusanya OO, de Claro RA, Theoret MR, Smith BD, Norsworthy KJ. Sweet KL, et al. Among authors: smith bd. Clin Cancer Res. 2024 Jan 5;30(1):237-238. doi: 10.1158/1078-0432.CCR-23-3234. Clin Cancer Res. 2024. PMID: 38178776 No abstract available.
CML and the WHO: Why?
Berman E, Shah NP, Deninger M, Altman JK, Amaya M, Begna K, Bhatia R, Chan O, Collins R, Curtin P, DeAngelo DJ, Drazer M, Maness L, Metheny L, Mohan S, Moore J, Oehler V, Pratz K, Pusic I, Rose M, Shomali W, Smith BD, Styler M, Sweet K, Talpaz M, Tanaka T, Tantravahi S, Tsai S, Vaughn J, Welborn J, Yang D, Mauro M, Cortes J, Radich J, Druker B. Berman E, et al. Among authors: smith bd. J Clin Oncol. 2024 Mar 20;42(9):984-986. doi: 10.1200/JCO.23.01689. Epub 2023 Dec 12. J Clin Oncol. 2024. PMID: 38086008 No abstract available.
Outcome heterogeneity of TP53-mutated myeloid neoplasms and the role of allogeneic hematopoietic cell transplantation.
Pasca S, Haldar SD, Ambinder A, Webster JA, Jain T, Dalton WB, Prince GT, Ghiaur G, DeZern AE, Gojo I, Smith BD, Karantanos T, Schulz C, Stokvis K, Levis MJ, Jones RJ, Gondek LP. Pasca S, et al. Among authors: smith bd. Haematologica. 2024 Mar 1;109(3):948-952. doi: 10.3324/haematol.2023.283886. Haematologica. 2024. PMID: 37731390 Free PMC article. No abstract available.
Venetoclax in combination with hypomethylating agent for the treatment of advanced myeloproliferative neoplasms and acute myeloid leukemia with extramedullary disease.
Sanber K, Ye K, Tsai HL, Newman M, Webster JA, Gojo I, Ghiaur G, Prince GT, Gondek LP, Smith BD, Levis MJ, DeZern AE, Ambinder AJ, Dalton WB, Jain T. Sanber K, et al. Among authors: smith bd. Leuk Lymphoma. 2023 Apr;64(4):846-855. doi: 10.1080/10428194.2023.2173523. Epub 2023 Feb 6. Leuk Lymphoma. 2023. PMID: 36744656
Allogeneic Blood or Marrow Transplantation with High-Dose Post-Transplantation Cyclophosphamide for Acute Lymphoblastic Leukemia in Patients Age ≥55 Years.
Webster JA, Reed M, Tsai HL, Ambinder A, Jain T, Dezern AE, Levis MJ, Showel MM, Prince GT, Hourigan CS, Gladstone DE, Bolanos-Meade J, Gondek LP, Ghiaur G, Dalton WB, Paul S, Fuchs EJ, Gocke CB, Ali SA, Huff CA, Borrello IM, Swinnen L, Wagner-Johnston N, Ambinder RF, Luznik L, Gojo I, Smith BD, Varadhan R, Jones RJ, Imus PH. Webster JA, et al. Among authors: smith bd. Transplant Cell Ther. 2023 Mar;29(3):182.e1-182.e8. doi: 10.1016/j.jtct.2022.12.018. Epub 2022 Dec 29. Transplant Cell Ther. 2023. PMID: 36587740 Free PMC article.
Project Confirm: Accelerated Drug Approvals for Chronic Myeloid Leukemia.
Sweet KL, Cortes JE, Apperley JF, Mann M, Mauro MJ, Oehler VG, Ruiz C, Schiffer CA, Ehrlich LA, Pamuk GE, Wynne J, Mehta GU, de Claro RA, Theoret MR, Smith BD, Norsworthy KJ. Sweet KL, et al. Among authors: smith bd. Clin Cancer Res. 2023 Jun 13;29(12):2179-2183. doi: 10.1158/1078-0432.CCR-22-2628. Clin Cancer Res. 2023. PMID: 36547666 Free PMC article.
190 results